KALA BIO Secures Exclusive License to Younet AI's Researgency Platform
On March 4, 2026 Younet AI granted KALA BIO Inc. an exclusive worldwide license to its proprietary AI research platform Researgency for biotechnology applications. This collaboration could accelerate KALA BIO’s drug discovery by automating tasks and enhancing data-driven workflows through enterprise-grade AI infrastructure.
1. Exclusive License Agreement with Younet AI
On March 4, 2026, KALA BIO Inc. signed a Platform Development and Exclusive License Agreement with Younet AI, securing sole worldwide rights to the 'Researgency' AI research platform tailored for biotechnology applications.
2. Deployment of Researgency Platform
Researgency will enable KALA BIO to build customized AI models trained on proprietary data, automate repetitive research tasks, enhance productivity, and ensure compliance and data sovereignty within drug development workflows.
3. Impact on R&D Efficiency and Valuation
By integrating enterprise-grade AI infrastructure, KALA BIO aims to accelerate preclinical research timelines and improve workflow efficiency, which may strengthen clinical-stage pipelines and positively influence the company’s market valuation.